Author:
Falavarjani K Ghasemi,Modarres M,Nazari H
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581–611.
2. Beer PM, Wong SJ, Hammad AM, Falk NS, O’Malley MR, Khan S . Vitreous level of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26: 871–876.
3. Sivak-callcott JA, O'Day DM, Gass DM, Tsai JC . Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108: 1767–1776.
4. Oshima Y, Sakaguchi H, Gomi F, Tano Y . Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155–158.
5. Cheng JYC, Wong DWK, Ang CL . Intraocular Avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma. Ann Acad Med Singapore 2008; 37: 72–74.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献